All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Myeloproliferative neoplasms (MPN) in the blast phase (BP) are defined as ≥ 20% myeloblasts in the peripheral blood (PB) or bone marrow (BM)—this is seen in around 5–20% of patients with Philadelphia chromosome-negative MPN. The outcomes after allogeneic hematopoietic cell transplantation (HCT) in these patients are still not fully understood.
In this retrospective study, Vikas Gupta and colleagues investigated molecular, cytogenetic, and clinical factors in patients with MPN-BP and their association with outcome post allogeneic HCT.1 Their results have been recently published in Blood Advances and are summarized here.
177 patients with MPN-BP were identified from the Center for International Blood and Marrow Transplant Research database. Next-generation sequencing was possible in only 95 patients (54%), using a panel of 49 genes clinically relevant in hematologic malignancies.
The patients were also analyzed for the following endpoints:
DNA, deoxyribonucleic acid; ET, essential thrombocythemia; HCT, hematopoietic cell transplantation; MPN, myeloproliferative neoplasms; PMF, primary myelofibrosis; PV, primary myelofibrosis. |
|||
|
Sample DNA obtained |
No sample DNA obtained |
Total |
---|---|---|---|
Median age at HCT, years (range) |
59.9 |
58.48 |
58.75 |
Female sex, % |
32.6 |
36.6 |
34.5 |
Karnofsky index < 90%, % |
49.5 |
45.1 |
47.5 |
Type of MPN at diagnosis, % |
|
|
|
Cytogenetics, % |
|
|
|
Graft source, % |
|
|
|
Donor type, % |
|
|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox